Oral dydrogesterone versus micronized vaginal progesterone for luteal phase support: a double-blind crossover study investigating pharmacokinetics and impact on the endometrium.

MLA

Loreti, S., et al. “Oral Dydrogesterone versus Micronized Vaginal Progesterone for Luteal Phase Support: A Double-Blind Crossover Study Investigating Pharmacokinetics and Impact on the Endometrium.” Human Reproduction, vol. 39, no. 2, Feb. 2024, pp. 403–12. EBSCOhost, https://doi.org/10.1093/humrep/dead256.

APA

Loreti, S., Thiele, K., Brucker, M. D., Olsen, C., Centelles-Lodeiro, J., Bourgain, C., Waelput, W., Tournaye, H., Griesinger, G., Raes, J., Vieira-Silva, S., Arck, P., Blockeel, C., & Mackens, S. (2024). Oral dydrogesterone versus micronized vaginal progesterone for luteal phase support: a double-blind crossover study investigating pharmacokinetics and impact on the endometrium. Human Reproduction, 39(2), 403–412. https://doi.org/10.1093/humrep/dead256

Chicago

Loreti, S, K Thiele, M De Brucker, C Olsen, J Centelles-Lodeiro, C Bourgain, W Waelput, et al. 2024. “Oral Dydrogesterone versus Micronized Vaginal Progesterone for Luteal Phase Support: A Double-Blind Crossover Study Investigating Pharmacokinetics and Impact on the Endometrium.” Human Reproduction 39 (2): 403–12. doi:10.1093/humrep/dead256.